Replies to post #56811 on CV Sciences Inc (CVSI)

[deswag]

I totally agree. I have wondered about the viability of the ‘pharmaceutical’ division of the company since I put my first dollar in.

It sounds great and perhaps it was a viable option at one time. At present, IMHO they are better off focusing on scooping up market share before the likes of CGC and ACB come hunting for their own.

CVSI, CW and a few others have first mover advantage and should do everything in their power to solidify their business.

You’ve already got a brand recognition working here...just do your best with the thing you do best right now.

Of course there’s always room for innovation, new sku’s, whatever...but it’s a CPG arms race to a degree (again, imho).

Who knows...? Maybe one day the company has enough $ to go back down that road in the future.

[Wolf-man jack]

Kentucky Hempatise You count your blessings ant the Wolf will continue counting sheep you understand. I’m still searching for Mona’s agreement and what the milestones are arranged. The CVSI 007 is not completely dead. The Patent has been approved in Japan and in my opinion the company could form a joint venture with a Japanese or other ASEAN partnership company. The vesting by Mona depending on the Milestone effect could be slowed down at this point. Imo Have Mercy Wolf ahooooooo

On March 31, 2019, CV Sciences, Inc. (the “Company”) and Michael Mona, Jr. (“Mona”), the former President and Chief Executive Officer of CV Sciences, Inc. (the “Company”), entered into a Settlement Agreement (the “Settlement Agreement”), to which the Company agreed that Mona’s resignation from the Company on January 22, 2019 was for Good Reason (as defined in Mona’s Employment Agreement) and agreed to extend the deadline for Mona’s exercise of his stock options for a period of five (5) years. In exchange, Mona agreed that notwithstanding the terms of his Employment Agreement providing for acceleration of vesting of all stock options and Restricted Stock Units upon a Good Reason resignation, certain of his unvested stock options would not immediately vest, but rather continue to vest if, and only if, certain Company milestones are achieved related to the Company’s drug development efforts. These stock options were issued in July 2016 (6,000,000 options) and March 2017 (5,000,000 options). The Company and Mona also agreed to mutually release all claims arising out of and related to Mona’s resignation and separation from the Company.

https://www.marketwatch.com/press-release/cv-sciences-inc-otcmktscvsi-files-an-8-k-other-events-2019-04-02

Wolf Said; Mona Have Mercy Wolf ahooooooo

[Deetew]

We have to see first if they appeal or not, which would mean that the patent would still be pending since the finality of final rejections no longer applies after an appeal.